Argenx Reports Positive Results for Celiac Disease Drug

The experimental drug FB102 shows potential in protecting the intestinal lining during gluten exposure in a phase 2 trial.

Updated on Oct. 16, 2026 in Diabetes

A close-up, macro view of a clean, sculptural biological model depicting intestinal tissue structures in a clinical, laboratory-inspired environment. — Argenx SE reported positive phase 2 results for its experimental celiac disease treatment FB102, which effectively reduced intestinal damage during clinical trials. AI Illustration. Upload story photo >

Live Poll

Would you use a medication to protect against accidental gluten exposure if you have celiac disease?

Argenx SE announced positive phase 2 clinical trial results for its drug FB102, which aims to treat celiac disease by blocking specific immune responses. The treatment successfully reduced signs of intestinal injury in patients during a controlled eight-week gluten challenge.

Why it matters

Celiac disease currently lacks a pharmacological treatment, leaving many patients to manage persistent symptoms despite a gluten-free diet. Targeting CD122 receptors offers a new mechanism to potentially prevent the inflammation that causes intestinal damage.

The phase 2 trial enrolled 126 patients who underwent an eight-week gluten challenge, with researchers analyzing mucosal lining damage on day 78. These results remain non-peer-reviewed while the company prepares for further development.

The players

Argenx SE

This global biotechnology company focuses on developing antibody-based therapies to improve the lives of people suffering from severe autoimmune diseases.

The details

Administered intravenously, FB102 works by blocking CD122 receptors on specific T cells to stifle the inflammatory response that damages the gut. Researchers observed that treated participants exhibited less mucosal lining injury compared to those who received a placebo.

2009: Researchers demonstrated that CD122 blockade reversed intestinal damage in mouse models.
October 2026: Argenx announced the positive results from the phase 2 clinical trial.

Health Landscape

This development represents a potential move toward pharmacological intervention for celiac disease, which has historically relied solely on dietary management. The progression of the drug is now measured against the FDA's 52-week clinical trial efficacy requirement for chronic compounds.

Patients with celiac disease may eventually have an option to mitigate intestinal damage beyond a strict gluten-free diet. The drug is still in clinical testing and is not yet available for public use or medical prescription.

The takeaway

The study marks an early-stage milestone in using targeted receptor blocking to manage autoimmune reactions in the gut. While promising, the drug must still undergo further rigorous testing and peer review before reaching clinical practice.